Upload Image (Max 20MB per Image)
Omeros Corporation (NASDAQ: OMER) today announced positive results from a Phase 2a clinical trial of OMS824, the company's phosphodiesterase 10 (PDE10) inhibitor, in which the drug was well tolerated and demonstrated comparable systemic ...
Tags: NASDAQ, PDE, PET, OM824